In previous studies, we detected CAdVEC-derived PD-L1 antibody at treated tumor sites but not in blood samples (6), suggesting that PD-L1 antibody produced by our CAdVEC will not lead to the systemic toxicities seen in patients systemically infused with immune checkpoint inhibitor (ICI) (14). Here, CD274 is linked to neoplasm.